Diagnosis of Vascular Ehlers-Danlos Syndrome
Vascular EDS diagnosis requires identification of a pathogenic COL3A1 variant through genetic testing—clinical criteria alone are insufficient and lead to misdiagnosis. 1
Diagnostic Approach
1. Clinical Suspicion Triggers
Look for these specific features that should prompt genetic testing:
Major diagnostic features:
- Arterial dissection, aneurysm, or rupture (especially in medium-sized arteries)
- Spontaneous sigmoid colon perforation
- Uterine rupture during pregnancy (outside labor/delivery)
- Carotid-cavernous sinus fistula formation 1
Characteristic physical findings:
- Thin, translucent skin with visible veins (48.8% of confirmed cases)
- Easy bruising (64% of confirmed cases)
- Characteristic facial appearance (thin nose, thin lips, small earlobes, prominent eyes)
- Acrogeria (aged appearance of hands) 2, 3
2. Genetic Testing: The Definitive Diagnostic Standard
Molecular confirmation is mandatory—identification of a causal COL3A1 variant is required for diagnosis. 1 Clinical diagnostic criteria have poor specificity and lead to overdiagnosis.
Key evidence on diagnostic accuracy:
- The Villefranche clinical criteria have only 60% specificity, meaning 40% of patients meeting clinical criteria do NOT have vEDS 3
- Among 173 patients diagnosed with "vEDS," 76 (44%) were diagnosed by clinical criteria alone without molecular confirmation—these patients had significantly different features including higher rates of mitral valve prolapse (10.5% vs 1.2%) and joint hypermobility (68.4% vs 40.7%), suggesting misdiagnosis 2
- Clinical criteria perform worst in patients ≤25 years old 3
Genetic testing methods:
- Direct COL3A1 gene sequencing (detects point mutations, splice site variants)
- Copy number variation analysis (detects deletions/duplications)
- Amplification-based next-generation sequencing panels can detect the full spectrum of variants including multi-exon deletions 4
Critical caveat: Not all COL3A1 variants are pathogenic—interpretation by a geneticist trained in variant assessment is essential 2. Null variants (no gene product) actually show better prognosis than missense variants 1.
3. Biochemical Testing (Optional Screening)
SDS-PAGE analysis of type III procollagen from cultured skin fibroblasts can serve as a screening tool before genetic testing:
- Shows intracellular retention, reduced secretion, and overmodification of α1 chains of procollagen III in vEDS
- Has excellent negative predictive value—abnormalities of procollagen III were not observed in patients without vEDS 5
- However, genetic testing is still required for definitive diagnosis 6
Post-Diagnosis Baseline Imaging
Once genetic diagnosis is confirmed, obtain baseline vascular imaging from head to pelvis (CT angiography or MRI) to evaluate the entire aorta and branch vessels 7, 1. This establishes a baseline for surveillance, though notably arteries may rupture or dissect even without significant dilation 7.
Common Diagnostic Pitfalls
Relying on clinical criteria alone: This leads to misdiagnosis of patients with hypermobile EDS or other connective tissue disorders as vEDS 2
Assuming coagulation disorder in children: Many children with vEDS are initially misdiagnosed with bleeding disorders due to easy bruising 6
Missing the diagnosis in young patients: Clinical features may not be fully manifest in adolescents and young adults, yet vascular complications can begin during adolescence 1, 3
Failing to perform family screening: Once a pathogenic variant is identified, cascade genetic screening of family members is essential 8
Genotype-Phenotype Correlation
The specific COL3A1 variant affects prognosis: